Back to Journals » Clinical Ophthalmology » Volume 8

Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye

Authors Hahn P

Received 26 August 2014

Accepted for publication 17 September 2014

Published 17 October 2014 Volume 2014:8 Pages 2129—2131


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser

Paul Hahn

Duke Eye Center, Duke University Medical Center, Durham, NC, USA

Abstract: Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy in vitrectomized eyes remains a challenge due to the reduced half-life of these agents. Aflibercept may have stronger binding activity and a longer intravitreal half-life compared to bevacizumab and ranibizumab, but its use in postvitrectomy eyes has not been reported. We present a case of an 89-year-old female, with recurrent choroidal neovascularization 10 years following prior macular translocation vitrectomy surgery for neovascular age-related macular degeneration, successfully treated with monthly aflibercept injections initiated following poor response to a single initial bevacizumab injection. This report suggests that aflibercept may be an important treatment option for vitrectomized eyes requiring anti-VEGF treatment.

Keywords: anti-VEGF, vitrectomized, aflibercept, neovascular age-related macular degeneration

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]